此页面是自动翻译的，不保证翻译的准确性。请参阅 英文版 对于源文本。

Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer

2017年12月3日 更新者：Masonic Cancer Center, University of Minnesota

Phase II Trial of Neoadjuvant Therapy With Carboplatin and Gemcitabine With Thalidomide in Patients With Stage II and IIIA Non-Small Cell Lung Cancer

RATIONALE: Drugs used in chemotherapy, such as carboplatin and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Thalidomide may stop the growth of tumor cells by blocking blood flow to the tumor. Giving carboplatin and gemcitabine together with thalidomide before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

PURPOSE: This phase II trial is studying how well giving carboplatin and gemcitabine together with thalidomide works in treating patients who are undergoing surgery for stage II or stage III non-small cell lung cancer.

研究概览

地位

终止

条件

干预/治疗

详细说明

OBJECTIVES:

Primary

  • Determine the complete and partial response rates in patients with stage II or IIIA non-small cell lung cancer treated with neoadjuvant carboplatin, gemcitabine hydrochloride, and thalidomide.

Secondary

  • Determine, preliminarily, the mechanism of action and activity of thalidomide against lung cancer.
  • Determine the 1-year and 2-year survival of patients treated with this regimen.
  • Determine the toxicity of this regimen in these patients.
  • Determine the operative mortality of patients treated with this regimen.

OUTLINE: This is a pilot study.

Patients receive carboplatin intravenously (IV) over 30 minutes on day 1, gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and oral thalidomide once daily on days 1-21. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Within 2-6 weeks after the completion of chemotherapy, patients with resectable tumors undergo surgical resection.

After completion of study treatment, patients are followed every 3 months for 2 years.

研究类型

介入性

注册 (实际的)

22

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。

学习地点

  • 美国
    • Minnesota
      • Minneapolis、Minnesota、美国、55455
        • University of Minnesota Cancer Center
      • Robbinsdale、Minnesota、美国、55422-2900
        • Hubert H. Humphrey Cancer Center at North Memorial Outpatient Center
    • New Hampshire
      • Lebanon、New Hampshire、美国、03756-0002
        • Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Histologically or cytologically confirmed non-small cell lung cancer (NSCLC), including any of the following histologic subtypes:

    • Squamous cell carcinoma
    • Adenocarcinoma
    • Large cell undifferentiated carcinoma
  • Stage II or IIIA disease
  • Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral Computerized Axial Tomography (CT) scan
  • No tumor involving the superior sulcus (e.g., Pancoast tumor)
  • Karnofsky performance status 70-100%
  • Absolute neutrophil count ≥ 1,500/mm^3
  • Platelet count ≥ 100,000/mm^3
  • Creatinine ≤ 2 mg/dL
  • Bilirubin < 2 mg/dL
  • Aspartate aminotransferase (AST) < 3 times upper limit of normal

Exclusion Criteria:

  • Pregnant or nursing

    • No nursing during and for ≥ 4 weeks after completion of study treatment
  • Positive pregnancy test
  • Fertile female patients must use 2 effective methods of contraception 4 weeks before, during, and for 4 weeks after completion of study treatment
  • Fertile male patients must use effective barrier contraception during and for 4 weeks after completion of study treatment
  • Blood, sperm, or ova donation during study treatment
  • Post obstructive pneumonia
  • Other serious infection or medical illness that would preclude study participation
  • Other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or other malignancy that is unlikely to affect survival for the next 3 years
  • Less than 5 years since prior resection of lung disease
  • Prior systemic chemotherapy or radiotherapy for non-small cell lung cancer (NSCLC)
  • Other concurrent chemotherapy or radiotherapy
  • Concurrent hormonal therapy or immunotherapy
  • Other concurrent anticancer therapy
  • Other concurrent investigational agents
  • Concurrent participation in another clinical study

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

  • 主要用途：治疗
  • 分配：非随机化
  • 介入模型：单组作业
  • 屏蔽：无（打开标签）

武器和干预

参与者组/臂
干预/治疗
实验性的：Treatment Arm
Chemotherapy treatment (carboplatin, gemcitabine and thalidomide) every 21 days for 3 courses.
药品：carboplatin
Day 1 of Cycles 1, 2 and 3 - intravenously (IV) 30 minutes (Area Under the Curve = 5.5)
其他名称：
  • 铂金
药品：gemcitabine hydrochloride
Days 1 and 8 of Cycles 1, 2 and 3 - 30 minute IV, 1000 mg/m2.
其他名称：
  • 金扎
药品：thalidomide
Oral administration: Cycle 1 - Day 1 50 mg, Day 2 100 mg, Day 3 150 mg, Day 4 and continuing until end of study treatment 200 mg.
其他名称：
  • 沙利度胺
程序：conventional surgery
Resection - between 2 and 6 weeks following last dose of chemotherapy.
其他名称：
  • 手术
  • 切除

研究衡量的是什么？

主要结果指标

结果测量
措施说明
大体时间
Number of Patients Reporting Clinical Response
大体时间：At end of 3 -21 day cycles of treatment
Objective clinical response measuring using tumor assessments: Complete Response (CR) = disappearance of all target and non-target lesions and normalization of tumor marker level, if applicable. Pathological Complete Response (PCR) = No viable tumor cells in specimen determined by light microscopy. Partial Response (PR) = at least 30% decrease in the sum of longest diameter of target lesions from baseline. Progressive Disease (PD) = at least 20% increase in the sum of longest diameters of target lesions from baseline or new lesions. Stable Disease (SD) = Neither PR or PD.
At end of 3 -21 day cycles of treatment

次要结果测量

结果测量
措施说明
大体时间
Number of Patients Disease-free at 1 Year
大体时间：1 year
Calculated from date of enrollment to date of recurrence or death, whichever came first
1 year
Number of Patients Disease-free at 2 Years
大体时间：2 Years
Calculated from date of enrollment to date of recurrence or death, whichever came first
2 Years
Number of Patients Alive at 1 Year (Survival)
大体时间：12 Months
Participants who were alive at one year from date of enrollment .
12 Months
Number of Patients Alive at 2 Years (Survival)
大体时间：24 Months
Participants who were alive at 2 years from date of enrollment.
24 Months
Number of Patients Alive at 56 Months (End of Study)
大体时间：Up to 56 months
Patients alive from date of enrollment to date of death or censored at date of last contact (Overall Survival).
Up to 56 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

Masonic Cancer Center, University of Minnesota

调查人员

  • 学习椅：Arkadiusz Dudek, MD、Masonic Cancer Center, University of Minnesota

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2002年5月1日

初级完成 (实际的)

2008年3月1日

研究完成 (实际的)

2008年7月1日

研究注册日期

首次提交

2006年1月24日

首先提交符合 QC 标准的

2006年1月24日

首次发布 (估计)

2006年1月25日

研究记录更新

最后更新发布 (实际的)

2017年12月28日

上次提交的符合 QC 标准的更新

2017年12月3日

最后验证

2017年12月1日

更多信息

与本研究相关的术语

关键字

其他相关的 MeSH 术语

其他研究编号

  • 2002LS013
  • LILLY-X-382 (其他标识符：Eli Lilly)
  • 0202M17981 (其他标识符：IRB, University of Minnesota)

此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.

carboplatin的临床试验

搜索类似试验

赞助者和合作者

医疗条件

药物干预

CROs by country

CROs in Cyprus

条件

罕见疾病

药物干预

膳食补充剂

赞助者/合作者

地点

3
订阅